Building Robust Manufacturing & Quality Systems to Enable the Commercialization of TIL Therapies
- Establishing CMC quality systems that support consistent TIL manufacturing from early development through commercialization
- Exploring lessons learned from scaling autologous cell therapies from research to industrial manufacturing while maintaining product quality and regulatory compliance
- Navigating global regulatory expectations and integrating manufacturing, quality, and clinical development strategies to accelerate TIL therapy approval and commercialization